MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.

NCT03611556 PHASE1, PHASE2 COMPLETED Results posted

The objective of this study is to evaluate the safety, tolerability, and antitumor activity of oleclumab (MEDI9447) in combination with or without durvalumab plus chemotherapy in participants with metastatic pancreatic cancer.

Details

Lead sponsor	MedImmune LLC
Phase	PHASE1, PHASE2
Status	COMPLETED
Enrolment	213
Start date	Thu Jun 21 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Jul 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Carcinoma
• Metastatic Pancreatic Adenocarcinoma

Interventions

• Oleclumab
• Durvalumab
• Gemcitabine
• Nab-paclitaxel
• Oxaliplatin
• Folinic acid
• 5-FU

Countries

United States, Australia, Spain, Norway